Aveanna Healthcare Holdings Inc. Common Stock (AVAH)

FairStock Score: 85/100 — HIGH CONVICTION

Key Financials

Strengths

• Generates $79 million in annual free cash flow (5.6% yield on market cap)
• High return on equity of 615.7% demonstrating efficient capital deployment
• Revenue growth of 27.4% demonstrates strong top-line momentum
• FairStock composite score of 85/100 places it in the top tier across value, quality, and momentum factors

Concerns

• High leverage at 7.76x debt-to-equity increases financial risk and interest expense burden
• Altman Z-Score of 0.2 places it in the financial distress zone—elevated bankruptcy risk

AI Analysis

Aveanna Healthcare Holdings Inc. Common Stock is a micro-cap healthcare company valued at $1.4 billion. The business generates $2.4 billion in annual revenue with a 7.3% net margin and $79 million in free cash flow. From a quality standpoint, Aveanna shows distressed Altman Z-Score of 0.2 warrants caution and extraordinary 616% return on equity. On valuation, the stock is deeply undervalued on a P/E basis at 6.2x, with trades above its Graham Number with a negative 39% margin. Growth dynamics show revenue growing at 27.4% and profit growth of 512.6%. Our composite FairStock Score of 85/100 reflects strong fundamentals overall. Investors should weigh the business quality against the current price and their own margin of safety requirements.

Bull Case

Aveanna's 27% revenue growth trajectory could accelerate as it captures additional market share in the healthcare sector. With $79 million in annual free cash flow (5.6% yield), management has ample capital for buybacks, dividends, or accretive acquisitions.

Bear Case

Elevated leverage at 7.8x D/E means rising interest rates or revenue weakness could strain debt covenants and force asset sales at distressed prices. Regulatory changes, input cost inflation, or demand normalization represent underappreciated risks that could materially impact forward estimates.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer